ERBB2 and invasive carcinoma: Core needle biopsy revealed an invasive carcinoma of no special type, with estrogen receptor positivity in 90% of tumor cells, progesterone receptor positivity in 5%, and human epidermal growth factor receptor 2 (HER2) negativity assessed by immunohistochemistry (IHC), with a score of 0.